The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-02-10
Просмотров: 81
Описание:
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the potential for discontinuing lenalidomide maintenance after high-dose therapy in patients with multiple myeloma. Dr Dimopoulos discusses a study where patients with sustained measurable residual disease (MRD) negativity who had received at least three years of lenalidomide maintenance were allowed to discontinue treatment, with the majority maintaining MRD negativity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
